Jump to content

BW-501C67: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
m SafariScribe moved page Draft:BW-501C67 to BW-501C67: Publishing accepted Articles for creation submission (AFCH)
Cleaning up accepted Articles for creation submission (AFCH)
Line 1: Line 1:
{{Short description|Peripheral serotonin antagonist}}
{{Short description|Peripheral serotonin antagonist}}

{{Draft topics|chemistry|medicine-and-health}}
{{AfC topic|stem}}
{{AfC submission|||ts=20241114035331|u=76.174.0.57|ns=118}}
{{AfC submission|t||ts=20241114035310|u=76.174.0.57|ns=118|demo=}}<!-- Important, do not remove this line before article has been created. -->
{{Infobox drug
{{Infobox drug
| drug_name =
| drug_name =
Line 78: Line 75:
==References==
==References==
{{Reflist}}
{{Reflist}}



{{Serotonin receptor modulators}}
{{Serotonin receptor modulators}}
Line 87: Line 83:
[[Category:Chloroarenes]]
[[Category:Chloroarenes]]
[[Category:Peripherally selective drugs]]
[[Category:Peripherally selective drugs]]


{{Pharmacology-stub}}

Revision as of 04:29, 14 November 2024

BW-501C67
Clinical data
Other namesBW-501; BW-501C; α-Anilino-N-2-(3-chlorophenoxy)-propylacetamidine
Drug classPeripherally selective serotonin receptor antagonist
Identifiers
  • 2-anilino-N'-[3-(2-chlorophenoxy)propyl]ethanimidamide
PubChem CID
ChemSpider
Chemical and physical data
FormulaC17H20ClN3O
Molar mass317.82 g·mol−1
3D model (JSmol)
  • C1=CC=C(C=C1)NCC(=NCCCOC2=CC=CC=C2Cl)N
  • InChI=1S/C17H20ClN3O/c18-15-9-4-5-10-16(15)22-12-6-11-20-17(19)13-21-14-7-2-1-3-8-14/h1-5,7-10,21H,6,11-13H2,(H2,19,20)
  • Key:IKCBXYTYVXLXIR-UHFFFAOYSA-N

BW-501C67 is a peripherally selective serotonin 5-HT2A receptor antagonist which is used in scientific research.[1][2][3][4][5] It shows selectivity for the serotonin 5-HT2A receptor over the α1-adrenergic receptor.[1]

The drug antagonizes peripheral but not central effects of serotonin receptor agonists like serotonin.[2][3][6][5] As examples, it has been found to antagonize the sympathomimetic effects of serotonin in animals, including vasoconstriction and pressor effects, but does not block centrally mediated effects like increased corticosterone secretion or myoclonus.[3][6][7][5]

BW-501C67 and analogues were patented for use in combination with serotonin 5-HT2A receptor agonists like serotonergic psychedelics in 2023.[8]

See also

References

  1. ^ a b Middlemiss, Derek N.; Hibert, Marcel; Fozard, John R. (1986). "Chapter 5. Drugs Acting at Central 5-Hydroxytryptamine Receptors". Annual Reports in Medicinal Chemistry. Vol. 21. Elsevier. p. 41–50. doi:10.1016/s0065-7743(08)61115-x. ISBN 978-0-12-040521-3.
  2. ^ a b Sharp T, Boothman L, Raley J, Quérée P (December 2007). "Important messages in the 'post': recent discoveries in 5-HT neurone feedback control". Trends Pharmacol Sci. 28 (12): 629–636. doi:10.1016/j.tips.2007.10.009. PMID 17996955.
  3. ^ a b c Green AR (December 1984). "5-HT-mediated behavior. Animal studies". Neuropharmacology. 23 (12B): 1521–1528. doi:10.1016/0028-3908(84)90096-0. PMID 6152026.
  4. ^ Ramage AG (November 2001). "Central cardiovascular regulation and 5-hydroxytryptamine receptors". Brain Res Bull. 56 (5): 425–439. doi:10.1016/s0361-9230(01)00612-8. PMID 11750788.
  5. ^ a b c Fuller RW, Kurz KD, Mason NR, Cohen ML (June 1986). "Antagonism of a peripheral vascular but not an apparently central serotonergic response by xylamidine and BW 501C67". Eur J Pharmacol. 125 (1): 71–77. doi:10.1016/0014-2999(86)90084-1. PMID 3732393.
  6. ^ a b Cook DA (1984). "The pharmacology of cerebral vasospasm". Pharmacology. 29 (1): 1–16. doi:10.1159/000137986. PMID 6379682.
  7. ^ Fuller RW (1996). "Serotonin receptors involved in regulation of pituitary-adrenocortical function in rats". Behav Brain Res. 73 (1–2): 215–219. doi:10.1016/0166-4328(96)00099-x. PMID 8788505.
  8. ^ "Combinations of peripheral 5-ht2a receptor antagonists and central 5-ht2a receptor agonists". Google Patents. 2 March 2023. Retrieved 14 November 2024.